Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
175 rows where has_cryoEM = 1, has_known_aptamer = 1 and in_cev_map = 0 sorted by evidence_priority descending
This data as json, CSV (advanced)
surface_class 5
- B_cargo 67
- A_surface 60
- A_assoc 40
- A2_pm_peripheral 6
- unknown 2
in_cev_map 1
- - · 175 ✖
has_structure 1
- 1 175
has_known_aptamer 1
- 1 · 175 ✖
has_cryoEM 1
- 1 · 175 ✖
has_activation_state_pdb_pair 1
- 0 175
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P13569 | CFTR | Cystic fibrosis transmembrane conductance regulator | Tier 1 | 0.824 | 1 | A_surface | 58 | 75.62 | 1 | 0 | 1 | 10 | 41148207, 31029337, 30595527, 22483890, 15657417 | 0 | cystic fibrosis | 0.9133535862571094 | ||
| P07949 | RET | Proto-oncogene tyrosine-protein kinase receptor Ret | Tier 1 | 0.809 | 1 | A_surface | 34 | 78.81 | 1 | 0 | 1 | 83 | 41962371, 41744190, 41636718, 41526122, 41406741, 41171123, 41082837, 41060784, 41027166, 40932619, 40815127, 40711581, 40633058, 40602121, 40410423, 40285964, 40252505, 40222299, 39344894, 39288589, 39190775, 38953438, 38876068, 38852325, 38718747, 38604287, 38354543, 38282384, 38237282, 37851382, 37774402, 37757695, 37437453, 37245460, 36952259, 36315022, 35550937, 35420408, 34342436, 34132907, 34016094, 33513536, 33462661, 33119785, 33011620, 32760976, 32527800, 32212604, 32138930, 31897454 | 0 | medullary thyroid gland carcinoma | 0.8617460262224842 | ||
| Q12809 | KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | Tier 1 | 0.806 | 1 | A_surface | 23 | 62.75 | 1 | 0 | 1 | 1 | 22617876 | 0 | Romano-Ward syndrome | 0.8549238933917284 | ||
| P31785 | IL2RG | Cytokine receptor common subunit gamma | Tier 1.5 | 0.804 | 1 | A_surface | 14 | 75.5 | 1 | 0 | 1 | 2 | 30800133, 33869115 | 0 | gamma chain deficiency | 0.8469997000418428 | ||
| P08100 | RHO | Rhodopsin | Tier 1.5 | 0.804 | 1 | A_surface | 4 | 88.75 | 1 | 0 | 1 | 45 | 41963275, 41924874, 41636061, 40808302, 40642289, 40330320, 40045571, 39863313, 39788632, 38070612, 37191882, 36705086, 36696850, 36095194, 36049339, 35622174, 34709779, 34471566, 32696702, 32479610, 32319623, 32119944, 31737572, 31588238, 31535128, 29570714, 29281176, 28648779, 27893356, 25645980, 23757206, 23701883, 25033804, 22689339, 22302221, 22121695, 19766091, 19389625, 16419035, 12123800, 8743323, 7678562, 19188685, 18230760 | 0 | retinitis pigmentosa | 0.8481942240861982 | ||
| P07911 | UMOD | Uromodulin | Tier 1 | 0.803 | 1 | A_surface | 10 | 82.94 | 1 | 0 | 1 | 4 | 37533140, 35446786 | 0 | familial juvenile hyperuricemic nephropathy type 1 | 0.8446536377993564 | ||
| O95342 | ABCB11 | Bile salt export pump | Tier 1.5 | 0.801 | 1 | A_surface | 8 | 83.12 | 1 | 0 | 1 | 1 | 36313979 | 0 | progressive familial intrahepatic cholestasis type 2 | 0.8372060401943777 | ||
| P16473 | TSHR | Thyrotropin receptor | Tier 1 | 0.8 | 1 | A_surface | 9 | 74.0 | 1 | 0 | 1 | 6 | 41054857, 40997970, 40588369, 38650837 | 0 | hypothyroidism due to TSH receptor mutations | 0.8327127196409464 | ||
| Q92736 | RYR2 | Ryanodine receptor 2 | Tier 1 | 0.8 | 1 | A_surface | 26 | 1 | 0 | 1 | 1 | 24130701 | 0 | catecholaminergic polymorphic ventricular tachycardia 1 | 0.8338648743498255 | |||
| Q9ULV1 | FZD4 | Frizzled-4 | Tier 1 | 0.795 | 1 | A_surface | 11 | 84.31 | 1 | 0 | 1 | 1 | 18673242 | 0 | Familial exudative vitreoretinopathy | 0.8152111103672746 | ||
| Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | Tier 1 | 0.795 | 1 | A_surface | 7 | 62.0 | 1 | 0 | 1 | 2 | 25870409, 25558474 | 0 | Autosomal recessive early-onset inflammatory bowel disease | 0.8151052076044897 | ||
| P43220 | GLP1R | Glucagon-like peptide 1 receptor | Tier 1 | 0.78 | 1 | A_surface | 70 | 81.5 | 1 | 0 | 1 | 2 | 40691365, 30957581 | 0 | type 2 diabetes mellitus | 0.7667004144705459 | ||
| P51654 | GPC3 | Glypican-3 | Tier 1.5 | 0.779 | 1 | A_surface | 4 | 75.06 | 1 | 0 | 1 | 65 | 42083729, 41790019, 41653459, 41045695, 40825648, 40722645, 39998646, 39874791, 39608318, 39427046, 38910291, 38787447, 38621313, 38368644, 37665421, 36903516, 36457288, 36317566, 36072763, 35788872, 35699181, 35477501, 35051745, 34974867, 34306031, 33254049, 33080969, 32356075, 30347351, 30122918, 29675356, 29605994, 29277631, 27601357, 28263753 | 0 | Simpson-Golabi-Behmel syndrome type 1 | 0.762708583613362 | ||
| P20023 | CR2 | Complement receptor type 2 | Tier 1.5 | 0.776 | 1 | A_surface | 9 | 74.94 | 1 | 0 | 1 | 1 | 33235290 | 0 | immunodeficiency, common variable, 7 | 0.7543125403898414 | ||
| P04035 | HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Tier 1 | 0.774 | 1 | A_surface | 24 | 75.31 | 1 | 0 | 1 | 1 | 36470581 | 0 | Hypercholesterolemia | 0.7460937406970991 | ||
| P51681 | CCR5 | C-C chemokine receptor type 5 | Tier 1 | 0.773 | 1 | A_surface | 25 | 85.38 | 1 | 0 | 1 | 23 | 36576612, 33981364, 29678881, 29556342, 29301363, 27807347, 27652575, 26965267, 25794434, 25754473, 25329893, 23629001, 22811524, 21576818, 18799178, 16631118, 16227301, 15813986, 14610191, 12498773 | 0 | HIV infection | 0.7442590579227027 | ||
| P21860 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 | Tier 1 | 0.77 | 1 | A_surface | 23 | 72.44 | 1 | 0 | 1 | 9 | 40851486, 33770580, 33039492, 31846731, 31626948, 29440899, 23990977, 22733765, 18942860 | 0 | visceral neuropathy, familial, 1, autosomal recessive | 0.7335342096528644 | ||
| P08887 | IL6R | Interleukin-6 receptor subunit alpha | Tier 1.5 | 0.768 | 1 | A_surface | 10 | 77.88 | 1 | 0 | 1 | 18 | 40853309, 38152968, 37034659, 36579647, 35890412, 33590853, 33340765, 32515246, 29211023, 28929152, 26552813, 26383776, 24481022, 24440854, 23235494, 22503683, 22258147, 22094809 | 0 | rheumatoid arthritis | 0.7269057706798291 | ||
| Q00975 | CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | Tier 1.5 | 0.767 | 1 | A_surface | 7 | 59.91 | 1 | 0 | 1 | 2 | 31118475, 25782368 | 0 | Seizure | 0.7217241968702018 | ||
| P47871 | GCGR | Glucagon receptor | Tier 1 | 0.766 | 1 | A_surface | 27 | 81.88 | 1 | 0 | 1 | 5 | 28775305, 23770039, 23744070 | 0 | GCGR-related hyperglucagonemia | 0.7213152740071143 | ||
| P40225 | THPO | Thrombopoietin | Tier 1 | 0.761 | 1 | A_surface | 3 | 61.44 | 1 | 0 | 1 | 2 | 38928037, 30312735 | 0 | thrombocythemia 1 | 0.7027329039559379 | ||
| Q9BYF1 | ACE2 | Angiotensin-converting enzyme 2 | Tier 1 | 0.758 | 1 | A_surface | 100 | 90.69 | 1 | 0 | 1 | 91 | 41716474, 41541792, 41274248, 40642289, 40333723, 40321580, 40227272, 39964138, 39923730, 39281706, 38973558, 38553521, 37932762, 37808754, 37692001, 37666993, 37385465, 37375202, 36950312, 36822303, 36714461, 36683236, 36581924, 36073793, 35972202, 35910791, 35907639, 35542182, 34876524, 34855379, 34847324, 34798263, 34696413, 34619249, 34458322, 34282416, 34248841, 34230708, 34230707, 34166652, 34123223, 33684258, 33683787, 33629859, 33561300, 33389440, 32981365, 32838280, 32551560, 36288301, 36170362, 35748608, 34953639 | 0 | COVID-19 | 0.6925739512122528 | ||
| P15391 | CD19 | B-lymphocyte antigen CD19 | Tier 1.5 | 0.755 | 1 | A_surface | 4 | 62.22 | 1 | 0 | 1 | 13 | 41079126, 40652441, 38661725, 38148412, 36095289, 35829681, 34680368, 34364920, 32401486, 31912987, 29928472, 21127492 | 0 | immunodeficiency, common variable, 3 | 0.6821072538733047 | ||
| Q96RJ3 | TNFRSF13C | Tumor necrosis factor receptor superfamily member 13C | Tier 1.5 | 0.748 | 1 | A_surface | 8 | 63.03 | 1 | 0 | 1 | 1 | 23470998 | 0 | immunodeficiency, common variable, 4 | 0.660711678987284 | ||
| P21554 | CNR1 | Cannabinoid receptor 1 | Tier 1 | 0.741 | 1 | A_surface | 32 | 71.69 | 1 | 0 | 1 | 1 | 19231809 | 0 | obesity | 0.6357831368051927 | ||
| Q8NER1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Tier 1.5 | 0.738 | 1 | A_surface | 8 | 71.94 | 1 | 0 | 1 | 2 | 40855286, 28604222 | 0 | migraine disorder | 0.6269329225883602 | ||
| P04233 | CD74 | HLA class II histocompatibility antigen gamma chain | Tier 1 | 0.737 | 1 | A_surface | 24 | 69.94 | 1 | 0 | 1 | 1 | 30899255 | 0 | non-small cell lung carcinoma | 0.6217636836935354 | ||
| P42658 | DPP6 | A-type potassium channel modulatory protein DPP6 | Tier 1.5 | 0.737 | 1 | A_surface | 8 | 86.69 | 1 | 0 | 1 | 1 | 41313574 | 0 | Autosomal dominant microcephaly | 0.6225938492787458 | ||
| P33681 | CD80 | T-lymphocyte activation antigen CD80 | Tier 1 | 0.735 | 1 | A_surface | 6 | 86.12 | 1 | 0 | 1 | 6 | 38473398, 37816286, 33742062, 33716989, 30417194, 30339905 | 0 | rheumatoid arthritis | 0.618273953289983 | ||
| P42081 | CD86 | T-lymphocyte activation antigen CD86 | Tier 1 | 0.735 | 1 | A_surface | 7 | 80.06 | 1 | 0 | 1 | 1 | 38473398 | 0 | rheumatoid arthritis | 0.615301066307767 | ||
| P35070 | BTC | Probetacellulin | Tier 1 | 0.724 | 1 | A_surface | 4 | 71.94 | 1 | 0 | 1 | 9 | 41627846, 41221651, 41168434, 40386592, 40259434, 38091146, 35852630, 35709524, 30869726 | 0 | cancer | 0.5807172419981024 | ||
| P18627 | LAG3 | Lymphocyte activation gene 3 protein | Tier 1.5 | 0.72 | 1 | A_surface | 6 | 78.38 | 1 | 0 | 1 | 6 | 40761795, 38158454, 36603108, 28934318 | 0 | melanoma | 0.5672649687930189 | ||
| Q9UEF7 | KL | Klotho | Tier 1 | 0.718 | 1 | A_surface | 6 | 89.06 | 1 | 0 | 1 | 19 | 41978019, 41851110, 41038766, 40370992, 39975897, 39909827, 38500260, 38233588, 37584531, 36891771, 36535944, 35770801, 35360393, 34375633, 33536505, 31511614, 25325398, 18569791, 40514411 | 0 | type 2 diabetes mellitus | 0.5587488336100863 | ||
| P15309 | ACP3 | Prostatic acid phosphatase | Tier 1 | 0.716 | 1 | A_surface | 17 | 92.25 | 1 | 0 | 1 | 3 | 41890985, 25591398 | 0 | prostate cancer | 0.5521391557206573 | ||
| Q9NP91 | SLC6A20 | Sodium- and chloride-dependent transporter XTRP3 | Tier 1 | 0.712 | 1 | A_surface | 10 | 93.12 | 1 | 0 | 1 | 1 | 35212764 | 0 | COVID-19 | 0.5415298766216101 | ||
| P55259 | GP2 | Pancreatic secretory granule membrane major glycoprotein GP2 | Tier 1.5 | 0.707 | 1 | A_surface | 4 | 78.62 | 1 | 0 | 1 | 3 | 36902059, 25483705, 24334484 | 0 | type 2 diabetes mellitus | 0.5235291484788168 | ||
| Q00604 | NDP | Norrin | Tier 1.5 | 0.707 | 1 | A_assoc | 11 | 83.56 | 1 | 0 | 1 | 2 | 39057719, 11352723 | 0 | Norrie disease | 0.8566451682188412 | ||
| O00206 | TLR4 | Toll-like receptor 4 | Tier 1 | 0.702 | 1 | A_surface | 15 | 89.19 | 1 | 0 | 1 | 32 | 41864915, 41444487, 40521190, 39897575, 38931862, 38742374, 38280803, 37360693, 36916435, 36908619, 35410404, 35402075, 35189346, 34831332, 32784904, 29910175, 29250957, 25483705 | 0 | major depressive disorder | 0.5065500149392951 | ||
| P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | Tier 1 | 0.702 | 1 | A_surface | 19 | 85.75 | 1 | 0 | 1 | 5 | 33495506, 29981048, 29327939, 28288993, 25901944 | 0 | anti-neutrophil cytoplasmic antibody-associated vasculitis | 0.5076734733894334 | ||
| P25106 | ACKR3 | Atypical chemokine receptor 3 | Tier 1.5 | 0.7 | 1 | A_surface | 14 | 82.44 | 1 | 0 | 1 | 2 | 40401615, 28670693 | 0 | oculomotor-abducens synkinesis | 0.49893280382434735 | ||
| P46094 | XCR1 | Chemokine XC receptor 1 | Tier 1.5 | 0.688 | 1 | A_surface | 1 | 84.94 | 1 | 0 | 1 | 1 | 35212764 | 0 | COVID-19 | 0.459103766220463 | ||
| P03971 | AMH | Anti-Muellerian hormone | Tier 1.5 | 0.685 | 1 | A_assoc | 3 | 68.62 | 1 | 0 | 1 | 2 | 41101154, 27364573 | 0 | persistent Mullerian duct syndrome | 0.7847328444470535 | ||
| P41231 | P2RY2 | P2Y purinoceptor 2 | Tier 1.5 | 0.681 | 1 | A_surface | 3 | 78.88 | 1 | 0 | 1 | 1 | 33911033 | 0 | nontoxic goiter | 0.43556889579550895 | ||
| P05019 | IGF1 | Insulin-like growth factor 1 | Tier 1 | 0.68 | 1 | A_assoc | 32 | 59.53 | 1 | 0 | 1 | 23 | 38384162, 35859339, 35591468, 33977395, 33467925, 32511241, 31930684, 26245346, 24832383, 23933187, 23373648, 16019422, 41283885, 39263947, 38497478, 33888746, 15231297 | 0 | growth delay due to insulin-like growth factor type 1 deficiency | 0.7650418939376437 | ||
| Q9GZV9 | FGF23 | Fibroblast growth factor 23 | Tier 1 | 0.679 | 1 | A_assoc | 6 | 76.62 | 1 | 0 | 1 | 11 | 39007037, 38079395, 35415885, 32065590, 30297602, 30197987, 41226313, 36705086 | 0 | autosomal dominant hypophosphatemic rickets | 0.762326334964193 | ||
| P32239 | CCKBR | Gastrin/cholecystokinin type B receptor | Tier 1.5 | 0.678 | 1 | A_surface | 5 | 75.75 | 1 | 0 | 1 | 2 | 33776434, 27754762 | 0 | gastroesophageal reflux disease | 0.4256110167566802 | ||
| P04201 | MAS1 | Proto-oncogene Mas | Tier 1.5 | 0.671 | 1 | A_surface | 3 | 83.5 | 1 | 0 | 1 | 10 | 40518278, 34016094, 30415442, 27936442, 23618401 | 0 | Abnormality of the skeletal system | 0.40450059258174326 | ||
| P41146 | OPRL1 | Nociceptin receptor | Tier 1.5 | 0.671 | 1 | A_surface | 4 | 82.31 | 1 | 0 | 1 | 1 | 14970396 | 0 | neurodegenerative disease | 0.4039002828932129 | ||
| P49238 | CX3CR1 | CX3C chemokine receptor 1 | Tier 1.5 | 0.67 | 1 | A_surface | 2 | 80.5 | 1 | 0 | 1 | 2 | 28727998 | 0 | age-related macular degeneration | 0.4006854573775187 | ||
| P35225 | IL13 | Interleukin-13 | Tier 1 | 0.669 | 1 | A_assoc | 13 | 85.62 | 1 | 0 | 1 | 9 | 41463156, 35356877, 33742062, 32784904, 27640094, 29949702, 21793788 | 0 | atopic eczema | 0.7297489019498119 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;